ArticleCardiology research and practice2026
Clinically Relevant Doses of Remimazolam Modulate Cardiac Electrophysiology: Late Repolarization Prolongation and Increased Conduction Dispersion With Preserved QTc.
Article in Cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinically Relevant Doses of Remimazolam Modulate Cardiac Electrophysiology: Late Repolarization Prolongation and Increased Conduction Dispersion With Preserved QTc.Cardiology research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Remimazolam, an ultra-short-acting benzodiazepine with rapid metabolism and cardiovascular stability, is increasingly used for anesthesia, yet its cardiac electrophysiologic effects are incompletely characterized. Methods: We conducted a multimodal evaluation in Langendorff-perfused guinea pig hearts and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), using surface electrocardiogram (ECG), multielectrode mapping, optical mapping, and whole-cell patch-clamp across remimazolam doses (0, 1, 2, 3 mg/kg/h). Results: High-dose remimazolam (3 mg/kg/h) prolonged the PR interval ( Conclusion: These findings indicate that at higher clinically relevant exposures, remimazolam selectively lengthens late repolarization and increases conduction heterogeneity-features consistent with an arrhythmogenic substrate-while QT and QTc remains stable, supporting cautious use and ECG monitoring in at-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.